6.
Dodd J, McLeod A, Windrim R, Kingdom J
. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev. 2010; (6):CD006780.
DOI: 10.1002/14651858.CD006780.pub2.
View
7.
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S
. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010; 116(2 Pt 1):402-414.
DOI: 10.1097/AOG.0b013e3181e9322a.
View
8.
Casu B, Vlodavsky I, Sanderson R
. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb. 2009; 36(3-4):195-203.
PMC: 2768601.
DOI: 10.1159/000175157.
View
9.
Askie L, Duley L, Henderson-Smart D, Stewart L
. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007; 369(9575):1791-1798.
DOI: 10.1016/S0140-6736(07)60712-0.
View
10.
Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P
. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012; 119(14):3269-75.
PMC: 3321853.
DOI: 10.1182/blood-2011-11-391383.
View
11.
Chui A, Murthi P, Gunatillake T, Brennecke S, Ignjatovic V, Monagle P
. Altered decorin leads to disrupted endothelial cell function: a possible mechanism in the pathogenesis of fetal growth restriction?. Placenta. 2014; 35(8):596-605.
DOI: 10.1016/j.placenta.2014.05.009.
View
12.
Rai R, Cohen H, Dave M, Regan L
. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997; 314(7076):253-7.
PMC: 2125731.
DOI: 10.1136/bmj.314.7076.253.
View
13.
Quaranta M, Erez O, Mastrolia S, Koifman A, Leron E, Eshkoli T
. The physiologic and therapeutic role of heparin in implantation and placentation. PeerJ. 2015; 3:e691.
PMC: 4304855.
DOI: 10.7717/peerj.691.
View
14.
Lemmon M, Dikic I, Ladbury J, Pinchasi D, Huang J, Jaye M
. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994; 79(6):1015-24.
DOI: 10.1016/0092-8674(94)90032-9.
View
15.
Greer I
. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999; 353(9160):1258-65.
DOI: 10.1016/S0140-6736(98)10265-9.
View
16.
Williams K
. Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Curr Opin Lipidol. 2001; 12(5):477-87.
DOI: 10.1097/00041433-200110000-00002.
View
17.
Lever R, Page C
. Non-anticoagulant effects of heparin: an overview. Handb Exp Pharmacol. 2012; (207):281-305.
DOI: 10.1007/978-3-642-23056-1_12.
View
18.
OGAMO A, Uchiyama H, Nagasawa K
. Separation of heparin into fractions with different anticoagulant activity by hydrophobic interaction chromatography. Biochim Biophys Acta. 1980; 626(2):477-85.
DOI: 10.1016/0005-2795(80)90144-0.
View
19.
Riffo-Vasquez Y, Somani A, Man F, Amison R, Pitchford S, Page C
. A Non-Anticoagulant Fraction of Heparin Inhibits Leukocyte Diapedesis into the Lung by an Effect on Platelets. Am J Respir Cell Mol Biol. 2016; 55(4):554-563.
DOI: 10.1165/rcmb.2015-0172OC.
View
20.
Greer I, Nelson-Piercy C
. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106(2):401-7.
DOI: 10.1182/blood-2005-02-0626.
View